Siblings 會議論文/會議摘要 [8/8] Collection Statistics 近3年內發表的文件:25(78.12%) 含全文筆數:32(100.00%) 文件下載次數統計 下載大於0次:32(100.00%) 下載大於100次:25(78.12%) 檔案下載總次數:5655(85.98%) 最後更新時間: 2024-12-01 08:29 Top Upload Loading... Top Download Loading... Recent Submissions Pathological response following neo... Clinical outcomes and histologic fi... Cytoplasmic lipid droplets predict ... A phase 1 study of biweekly nab-pac... Outcomes of post-immunotherapy dura... Impact of previous S-1 treatment on... Neuron-derived neurotensin promotes... Germline mutations of homologous re... Systemic treatments in pancreatic c... Pancreatic cancer cell-derived sema...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-25 of 32. (2 Page(s) Totally) 1 2 > >> View [10|25|50] records per page

Date	Title	Relation
2024-11	Cytoplasmic lipid droplets predict worse prognosis in diffuse large B-cell lymphoma: Next-generation sequencing deciphering lipogenic genes	American Journal of Surgical Pathology. 2024 Nov 1;48(11):1425-1438.
2024-11	Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis	Lancet. Oncology. 2024 Nov;25(11):1465-1475.
2024-10	A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study	Oncologist. 2024 Oct 3;29(10):e1396-e1405.
2024-08-28	Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab	Journal of Clinical Oncology. 2024 Aug 28;Article in Press.
2024-06	Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation	Biomedical Journal. 2024 Jun;47(3):Article number 100696.
2024-05	Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer	Pancreatology. 2024 May;24(3):600-607.
2024-02-15	Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway	American Journal of Cancer Research. 2024 Feb 15;14(2):448-466.
2024-02-13	Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan	Journal of Biomedical Science. 2024 Feb 13;31:Article number 21.
2024-02-01	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression	Liver Cancer. 2024 Feb 01;Article in Press.
2023-09-01	The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study	International Journal of Surgery. 2023 Sep 1;109(9):2614-2623.
2023-08-15	Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination	American Journal of Cancer Research. 2023 Aug 15;13(8):3417-3432.
2023-06	Investigation into the content of red material in EUS-guided pancreatic cancer biopsies	Gastrointestinal Endoscopy. 2023 Jun;97(6):1083-1091.e1.
2023-03	Tissue quality comparison between heparinized wet suction and dry suction in endoscopic ultrasound-fine needle biopsy of solid pancreatic masses: A randomized crossover study	Gut and Liver. 2023 Mar 15;17(2):318-327.
2023-02-05	Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer	Cancers. 2023 Feb 5;15(4):Article number 1008.
2023-02	The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan	ESMO Open. 2023 Feb;8(1):Article number 100746.
2022-11-15	The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma	American Journal of Cancer Research. 2022 Nov 15;12(11):5062-5073.
2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	Clinical Cancer Research. 2022 Oct 3;28(19):4248-4257.
2022-09-21	Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer	International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-06-22	Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study	Frontiers in Oncology. 2022 Jun 22;12:Article number 800842.
2022-06-02	Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma	Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
2022-06	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin	Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612.
2022-05-15	Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience	American Journal of Cancer Research. 2022 May 15;12(5):2189-2202.
2022-04-15	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan	American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898.
2022-04	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	British Journal of Cancer. 2022 Apr;126(7):1018-1026.
2022-02-24	Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway	International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608.

Showing items 1-25 of 32. (2 Page(s) Totally) 1 2 > >> View [10|25|50] records per page